Effect of Median Nerve Electrical Stimulation Combined With Auricular Acupuncture on Consciousness Disturbance in Patients With Craniocerebral Injury
ANECT-CCI
A Randomized Controlled Trial of Auricular Thumbtack Needle Therapy Combined With Conventional Treatment and Median Nerve Electrical Stimulation on Consciousness Recovery Prognosis and Family Satisfaction in Craniocerebral Injury Patients With Consciousness Disorder
1 other identifier
interventional
60
1 country
1
Brief Summary
This study aims to evaluate the effects of auricular press needle therapy, combined with conventional treatment and median nerve electrical stimulation, on promoting arousal and neurological recovery in patients with disorders of consciousness after traumatic brain injury. Sixty patients with a Glasgow Coma Scale (GCS) score of 4-8 were enrolled and randomly assigned in a 1:1 ratio to a control group or an experimental group (30 patients each). Both groups received standard conventional treatment (including surgery when indicated, medications, nutritional support, acupuncture, and complication prevention) combined with median nerve electrical stimulation. The experimental group received auricular press needle therapy (at Heart, Shenmen, Sympathetic, and Subcortex acupoints) on top of the same interventions, and family members were trained to perform daily acupoint massage. The GCS score and Coma Recovery Scale-Revised (CRS-R) score were assessed at baseline, 4 weeks, 6 weeks, and 8 weeks after the start of intervention, and the arousal rate was recorded. The Glasgow Outcome Scale (GOS) was used to evaluate prognosis at 1 month after the end of treatment, and family satisfaction was assessed using a Likert scale at 8 weeks post-intervention. Data were analyzed using SPSS Statistics 27.0, with statistical significance set at p \< 0.05.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Feb 2022
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 10, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 30, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
March 20, 2024
CompletedFirst Submitted
Initial submission to the registry
October 1, 2025
CompletedFirst Posted
Study publicly available on registry
December 10, 2025
CompletedDecember 10, 2025
November 1, 2025
1.8 years
October 1, 2025
December 7, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Awakening Rate of Patients with Consciousness Disorder After Traumatic Brain Injury (TBI)
1. Description Primary outcome is awakening rate at 8 weeks post-intervention in TBI patients with consciousness disorder (GCS 4-8). "Awakening" = independent eye-opening ≥30s, or clear responses (limb retraction, simple verbal answers) to verbal/pain stimuli, confirmed by 2 attending physicians. 2. Time Frame 8 weeks after intervention start (end of full course). 3. Assessment Method Record weekly awakening status during 8-week intervention; Count awakened patients in Arm 1 (control) and Arm 2 (experimental) at week 8; Calculate rate: (Awakened patients / Total patients per group) × 100%. 4. Rationale Awakening is core rehabilitation goal for these patients, directly reflecting intervention efficacy in consciousness recovery. More intuitive and clinically meaningful than other indicators (e.g., GCS) for evaluating core therapeutic effect.
8 weeks after the start of the intervention (which is the end of the full intervention course for the study).
Secondary Outcomes (1)
Change in Glasgow Coma Scale (GCS) Score
Baseline (pre-intervention), 4 weeks, 6 weeks, 8 weeks post-intervention.
Study Arms (2)
Conventional Treatment + Median Nerve Electrical Stimulation + Auricular Press-Needle Therapy
EXPERIMENTALConventional treatment combined with right median nerve electrical stimulation and auricular press-needle therapy.
Conventional Treatment + Median Nerve Electrical Stimulation
ACTIVE COMPARATORConventional treatment combined with right median nerve electrical stimulation.
Interventions
Routine comprehensive management for severe traumatic brain injury, including surgical intervention when indicated, intracranial pressure monitoring if needed, neuroprotective and symptomatic medications (e.g., anti-epileptic drugs), nutritional support, complication prevention, nursing care, and conventional rehabilitation therapy. All care was provided in accordance with institutional standard protocols.
The multifunctional electrical therapy apparatus (Model MT1023; Shenzhen Dongdixin Technology Co., Ltd.) was used. A single skin electrode was placed 2 cm proximal to the right wrist crease on the volar forearm. Stimulation parameters: asymmetric biphasic (direct current) square wave, intensity up to 20 mA, pulse width 300 ms, frequency 40 Hz, intermittent mode (20 seconds on, 40 seconds off). Sessions lasted 60 minutes and were delivered twice daily, 7 days per week, for 8 weeks.
Disposable sterile press needles (0.2 mm × 0.5 mm thumbtack type) were inserted bilaterally at the auricular acupoints Shenmen (TF4) and Subcortex/Brain (AT4) \[some records also included Heart (CO15) and Sympathetic\]. Needles were retained for 48 hours, replaced every 2-3 days, and the cycle was repeated for the entire 8-week treatment period. Family members were trained to massage each point three times daily.
Eligibility Criteria
You may qualify if:
- Disorder of consciousness following traumatic brain injury
- Stable vital signs with no evidence of active bleeding
- Glasgow Coma Scale (GCS) score between 4 and 8 (inclusive)
- No severe vital organ dysfunction and normal cardiac function
- Time from injury to enrollment ≤ 10 days
- No prior history of traumatic brain injury, epilepsy, or pregnancy
You may not qualify if:
- Presence of other critical illnesses (e.g., severe cardiovascular, hepatic, or renal disease)
- Known allergy to the electrodes or adhesive patches used in electrical stimulation
- Lack of cooperation or refusal by the patient's legal guardian/family members
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Li Hailead
Study Sites (1)
The First Affiliated Hospital of Gannan Medical University
Jiangxi, Ganzhou, 341000, China
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Hai N Li, Middle Initia
First Affiliated Hospital of Gannan Medical University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Chief Therapist, Department of Rehabilitation
Study Record Dates
First Submitted
October 1, 2025
First Posted
December 10, 2025
Study Start
February 10, 2022
Primary Completion
November 30, 2023
Study Completion
March 20, 2024
Last Updated
December 10, 2025
Record last verified: 2025-11
Data Sharing
- IPD Sharing
- Will not share
Patient Privacy Protection: Collected IPD includes sensitive personal health information. Per China's Personal Information Protection Law and hospital ethical requirements, sharing IPD risks unauthorized disclosure, violating patients' information security rights. Informed Consent Limitations : Participants' signed consent only authorizes IPD use for this study's research goals, not sharing with external parties. Without additional ethical approval and patient re-consent, sharing is non-compliant with ethical commitments. Data Security \& Integrity : IPD is managed under The First Affiliated Hospital of Gannan Medical University's security system. External sharing may cause data tampering, improper use, or loss, compromising result integrity and analysis credibility. Future IPD sharing (e.g., collaborative research) will require hospital Ethics Committee approval, patient re-consent, and strict de-identification/transfer protocols to meet legal and ethical standards.